Long-acting delivery systems for peptides: Inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules

T. W. Redding, Andrew V Schally, T. R. Tice, W. E. Meyers

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Intramuscular injection of [6-D-tryptophan]-luteinizing hormone-releasing hormone ([D-Trp6]LH-RH) in microcapsules of poly(DL-lactide-co-glycolide), designed to release a controlled dose of the peptide over a 30-day period, decreased the weights of androgen-dependent Dunning prostate tumors in rats and suppressed serum testosterone levels more effectively than daily subcutaneous administration of equivalent or double doses of unencapsulated [D-Trp6]LH-RH. The microcapsules or daily injections of [D-Trp6]LH-RH also significantly decreased tumor volumes. Microcapsules of [D-Trp6]LH-RH or related analogs that can be injected once a month should make the treatment of patients with prostate carcinoma and other neoplasms or disorders more convenient and efficacious.

Original languageEnglish
Pages (from-to)5845-5848
Number of pages4
JournalProceedings of the National Academy of Sciences of the United States of America
Volume81
Issue number18 I
StatePublished - Jan 1 1984
Externally publishedYes

Fingerprint

Gonadotropin-Releasing Hormone
Capsules
Prostate
Peptides
Injections
Neoplasms
Polyglactin 910
Intramuscular Injections
Tumor Burden
Tryptophan
Androgens
Testosterone
Carcinoma
Weights and Measures
Serum
Therapeutics

ASJC Scopus subject areas

  • General
  • Genetics

Cite this

@article{1e79592dd8a148da8a0bcf0eec4a8ed5,
title = "Long-acting delivery systems for peptides: Inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules",
abstract = "Intramuscular injection of [6-D-tryptophan]-luteinizing hormone-releasing hormone ([D-Trp6]LH-RH) in microcapsules of poly(DL-lactide-co-glycolide), designed to release a controlled dose of the peptide over a 30-day period, decreased the weights of androgen-dependent Dunning prostate tumors in rats and suppressed serum testosterone levels more effectively than daily subcutaneous administration of equivalent or double doses of unencapsulated [D-Trp6]LH-RH. The microcapsules or daily injections of [D-Trp6]LH-RH also significantly decreased tumor volumes. Microcapsules of [D-Trp6]LH-RH or related analogs that can be injected once a month should make the treatment of patients with prostate carcinoma and other neoplasms or disorders more convenient and efficacious.",
author = "Redding, {T. W.} and Schally, {Andrew V} and Tice, {T. R.} and Meyers, {W. E.}",
year = "1984",
month = "1",
day = "1",
language = "English",
volume = "81",
pages = "5845--5848",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "18 I",

}

TY - JOUR

T1 - Long-acting delivery systems for peptides

T2 - Inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules

AU - Redding, T. W.

AU - Schally, Andrew V

AU - Tice, T. R.

AU - Meyers, W. E.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - Intramuscular injection of [6-D-tryptophan]-luteinizing hormone-releasing hormone ([D-Trp6]LH-RH) in microcapsules of poly(DL-lactide-co-glycolide), designed to release a controlled dose of the peptide over a 30-day period, decreased the weights of androgen-dependent Dunning prostate tumors in rats and suppressed serum testosterone levels more effectively than daily subcutaneous administration of equivalent or double doses of unencapsulated [D-Trp6]LH-RH. The microcapsules or daily injections of [D-Trp6]LH-RH also significantly decreased tumor volumes. Microcapsules of [D-Trp6]LH-RH or related analogs that can be injected once a month should make the treatment of patients with prostate carcinoma and other neoplasms or disorders more convenient and efficacious.

AB - Intramuscular injection of [6-D-tryptophan]-luteinizing hormone-releasing hormone ([D-Trp6]LH-RH) in microcapsules of poly(DL-lactide-co-glycolide), designed to release a controlled dose of the peptide over a 30-day period, decreased the weights of androgen-dependent Dunning prostate tumors in rats and suppressed serum testosterone levels more effectively than daily subcutaneous administration of equivalent or double doses of unencapsulated [D-Trp6]LH-RH. The microcapsules or daily injections of [D-Trp6]LH-RH also significantly decreased tumor volumes. Microcapsules of [D-Trp6]LH-RH or related analogs that can be injected once a month should make the treatment of patients with prostate carcinoma and other neoplasms or disorders more convenient and efficacious.

UR - http://www.scopus.com/inward/record.url?scp=0038139821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038139821&partnerID=8YFLogxK

M3 - Article

C2 - 6237365

AN - SCOPUS:0038139821

VL - 81

SP - 5845

EP - 5848

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 18 I

ER -